BN Business News
Add your company to Business Communicator →

Labour market · 22/10/20261 min read

Georgiamune and the Menarini Group conclude an exclusive global licensing and collaboration agreement on GIM-621, an innovative oral immuno-oncological agent

Summary

GIM-621 is an innovative, preclinical, small molecule oral immunotherapy that has potential for application in the treatment of several solid tumours.

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →